Bayer stock has surged 83% over the past year, but valuation checks still point to a discount. The company trades at a price-to-sales ratio of 1.1 times, well below the pharmaceutical industry average of 2.6 times and a modelled fair ratio of 2.3 times. A new clinical trials alliance with the University of Colorado Anschutz supports future drug development, while the restructuring of the U.S. glyphosate business into Ruveon LLC highlights ongoing execution risk. The bull case sees Bayer as 21% undervalued, while the bear case argues it is 45% overvalued due to litigation exposures, including €1.2 billion in glyphosate provisions and €530 million for PCBs in the second quarter of 2025 alone. The debate centres on whether the market is overly penalising these risks or correctly pricing the chance they will continue to weigh on earnings.
Bayer AG NAStock rallied 83% but valuation screens show discount; bull case sees 21% undervalued, bear case 45% overvalued due to litigation risks.